Attributes | Values |
---|
rdf:type
| |
Description
| - Methotrexate (MTX) remains a mainstay in the treatment of children with hematological malignancies. However, a recent review of more than 40 trials for children with ALL concluded that the addition of high dose MTX (HDMTX) in many different doses and schedules did not improve CNS therapy and made only minor improvements in systemic therapy for children with ALL. Recent treatment schedules vary markedly in terms of timing, dosing and scheduling of MTX and/or leucovorin, which may leave us uncertain with ideas such as %22how should we best use HDMTX and LV?%22 Further clinical and pharmacological studies are actual even now, after more than 5 decades of clinical experiences with the MTX in pediatric oncology.
- Methotrexate (MTX) remains a mainstay in the treatment of children with hematological malignancies. However, a recent review of more than 40 trials for children with ALL concluded that the addition of high dose MTX (HDMTX) in many different doses and schedules did not improve CNS therapy and made only minor improvements in systemic therapy for children with ALL. Recent treatment schedules vary markedly in terms of timing, dosing and scheduling of MTX and/or leucovorin, which may leave us uncertain with ideas such as %22how should we best use HDMTX and LV?%22 Further clinical and pharmacological studies are actual even now, after more than 5 decades of clinical experiences with the MTX in pediatric oncology. (en)
- MTX zůstává hlavní léčebnou modalitou v terapii dětských hematologických malignit. Současný přehled více než 40 léčebných postupů u ALL dětského věku však naznačuje, že HDMTX podávané v mnoha diferentních dávkách a režimech nezlepšuje terapii CNS a působí jen menší zlepšení systémové terapie ALL dětí. Současné léčebné postupy se značně liší timingem, dávkami i režimem podání MTX a leukovorinu, což vyvolává otázku “ jaké je nejlepší užití HDMTX a LV?“ Takže i po 5 desetiletích klinických zkušeností s MTX v pediatrické onkologii jsou nutné a aktuální další klinické a farmakologické studie. (cs)
|
Title
| - High-dose methotrexate and/or Leucovorin rescue for the treatment of children with lymphoblastic malignancies
- High-dose methotrexate and/or Leucovorin rescue for the treatment of children with lymphoblastic malignancies (en)
- Vysoké dávky metotrexátu a/nebo leuceovorinu chrání děti s onemocněním lymfoblastickými malignitami (cs)
|
skos:prefLabel
| - High-dose methotrexate and/or Leucovorin rescue for the treatment of children with lymphoblastic malignancies
- High-dose methotrexate and/or Leucovorin rescue for the treatment of children with lymphoblastic malignancies (en)
- Vysoké dávky metotrexátu a/nebo leuceovorinu chrání děti s onemocněním lymfoblastickými malignitami (cs)
|
skos:notation
| - RIV/00209805:_____/05:#0000014!RIV06-MZ0-00209805
|
http://linked.open.../vavai/riv/strany
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00209805:_____/05:#0000014
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - leucovorin, High-dose methotrexate, lymphoblastic malignancies (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| |
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |